Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models-Reference-Cited by-同舟云学术

Activity of Clofazimine and TBI-166 against Mycobacterium tuberculosis in Different Administration Intervals in Mouse Tuberculosis Models

Published:2021-03-18 Issue:4 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Zhu Hui¹,Fu Lei¹,Wang Bin¹,Chen Xi¹,Zhao Jiaojie¹,Huang Haihong²,Lu Yu¹^ORCID

Affiliation:

1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China

2. Beijing Key Laboratory of Active Substance Discovery and Druggability Evaluation, Institute of Materia Medica, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China

Abstract

Clofazimine (CLO) and TBI-166 belong to the riminophenazine class of antimicrobial agent. TBI-166 exhibited promising antituberculosis activity in vitro and in animal models and is currently under phase I clinical development for the treatment of tuberculosis in China.

Funder

National Science and Technology Project of China

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02164-20

Reference19 articles.

1. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/

2. Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies

3. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

4. Assessment of Clofazimine Activity in a Second-Line Regimen for Tuberculosis in Mice

5. Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibiotics in the clinical pipeline as of December 2022;The Journal of Antibiotics;2023-06-08

2. Superior Efficacy of a TBI-166, Bedaquiline, and Pyrazinamide Combination Regimen in a Murine Model of Tuberculosis;Antimicrobial Agents and Chemotherapy;2022-09-20

3. Overcoming Mycobacterium tuberculosis through small molecule inhibitors to break down cell wall synthesis;Acta Pharmaceutica Sinica B;2022-08

4. Adapting Clofazimine for Treatment of Cutaneous Tuberculosis by Using Self-Double-Emulsifying Drug Delivery Systems;Antibiotics;2022-06-15